mRNA provides new therapeutic opportunities for a range of diseases. In vitro transcribed (IVT) mRNA's versatility lies in several key features: simplified cell-free manufacturing, cell cycle independent performance, and insertional-mutagenesis risk-free.
The simple and expedited mRNA manufacturing workflow offers more opportunities for personalized medicines, such as patient-specific cancer vaccines or protein replacement for rare diseases.
GenScript’s solution to mRNA production streamlines your workflow starting from gene synthesis to IVT mRNA production. mRNAs produced at GenScript are optimized with our proprietary production platform, ensuring the quality and expression efficiency of your mRNA.
|Identification||Appearance||Visual Inspect||Clear and free of foreign particles|
|RNA Length||Capillary Electrophoresis||Target ± 30%|
|RNA Length||Agarose Gel Electrophoresis||Expected size band detected|
|Poly A Length||Enzyme digestion and CE||Target ± 30%|
|RNA Content||UV Absorbance||Target ± 5%|
|PH||pH meter||Target ± 0.5|
|Buffer Specification||Client Spec||N/A|
|Purity||A 260/280 Ratio||UV Spec||1.70 ~ 2.30|
|Capping Efficiency||LC-MS||≥ 90%|
|Size based purity||Capillary Electrophoresis||≥75%|
|Impurity||Total protein residue||Nano Orange Assay||≤ 1%|
|Plasmid DNA Residue||qPCR||≤ 0.1%|
|Bioburden||Sdirect Inoculation||No Growth after
Note: Additional QC and characterizations are offered with an extra charge upon request.
Through this mRNA infographic you will learn about:
IVT mRNA’s key structural features and their function Composition of lipid nanoparticles as a main delivery vehicle IVT mRNA’s therapeutic modalities beyond prophylactic vaccines mRNA candidates progressing through clinical trials